Regencell Bioscience Limited (RGC) saw its stock price plummet 13.20% in pre-market trading on Friday, continuing a sharp downward trend that began earlier in the week. This latest decline follows significant drops of 18.69% in overnight trading and 18% on Wednesday, as investors rapidly reassess the company's valuation.

The sell-off appears to be triggered by a recent stock split announcement, which has prompted a broader reevaluation of Regencell's market position. This reassessment comes in the wake of an extraordinary rally that saw the stock surge by an astonishing 59,900% year-to-date, a move that has raised concerns given the company's lack of reported revenue.

Market analysts suggest that the current correction is a natural pullback after such a meteoric rise, especially considering the absence of fundamental financial performance to support the previous valuation. The biotech company's ability to maintain its market capitalization in the face of these fundamentals is now being questioned, resulting in the ongoing price correction. As investors continue to digest the implications of the stock split and reevaluate the company's prospects, RGC's stock may face further volatility in the near term.